Cancer scientists create 'human' leukemia process to map how disease begins, progresses
Cancer researchers led by Dr. John Dick at Ontario Cancer Institute (OCI) have developed a method to convert normal human blood cells into "human" leukemia stem cells. The converted cells, when transplanted into special mice that permit the growth of human cells, can replicate the entire disease process from the very moment it begins. The findings are published in the journal Science. Dr...
progresses at Biology Products
progresses at Biology Technology
progresses at Medicine News
Alzheimer's Disease Progresses Rapidly In Highly Educated
A recent study has now found that educated people could face increased risk from Alzheimer's disease, which is the most common cause of dementia in old people. // Although Alzheimer's tends to be associated with a later age of onset among the educated, it
progresses more rapidly. In other words, in highly educated people, a rapid decline is noted following onset of Alzheimer's manifes...
progresses at Medicine Products
progresses at Medicine Technology
Pieris Progresses Proprietary Asthma Program: Validation of
Pulmonary Delivery of Anticalin-Based Protein Product Candidate
FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...
Pieris Progresses Development of its Proprietary Biotherapeutics
Platform: Successful Demonstration of Dual Targeting With
Duocalin(R) Technology
FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...